M Holdings Securities Inc. Makes New $637,000 Investment in Teva Pharmaceutical Industries Ltd. $TEVA

M Holdings Securities Inc. purchased a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 15,965 shares of the company’s stock, valued at approximately $637,000.

Several other institutional investors have also recently made changes to their positions in TEVA. Root Financial Partners LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $33,000. Cornerstone Planning Group LLC increased its position in Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after buying an additional 755 shares in the last quarter. Western Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at about $43,000. Sunbelt Securities Inc. acquired a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $45,000. Finally, CX Institutional acquired a new position in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $42.38 on Wednesday. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59. The stock has a market cap of $49.38 billion, a PE ratio of 98.55, a price-to-earnings-growth ratio of 4.04 and a beta of 0.97. The stock’s fifty day simple moving average is $39.75 and its two-hundred day simple moving average is $34.90. Teva Pharmaceutical Industries Ltd. has a 1-year low of $24.01 and a 1-year high of $43.34.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.14. The firm had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.78 EPS. As a group, analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on TEVA shares. UBS Group raised their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Zacks Research downgraded Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. Leerink Partners upped their target price on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Finally, JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $47.23.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider owned 8,500 shares in the company, valued at approximately $330,225. This trade represents a 46.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Roberto Mignone sold 367,600 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 420,942 shares of company stock worth $16,572,473. 0.54% of the stock is owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.